Eau bactériostatique libre (1) 30 ml
avec des commandes qualifiées sur500 USD.
(exclut les produits de capsule, les peptides cosmétiques, les codes promotionnels et l'expédition)
HGH Fragment 176-191est un petit morceau synthétique d'hormone de croissance humaine naturelle (HGH). Il est souvent appelé «fragment lipolytique» pour sa capacité à stimuler la perte de graisse. Il a été démontré que cela aide à réduire la glycémie et à favoriser la guérison du cartilage sans augmenter la croissance osseuse du long, augmenter les niveaux d'IGF-1 ou modifier la sensibilité à l'insuline.
Utilisation du produit:Ce produit est conçu uniquement comme un produit chimique de recherche.Cette désignation permet l'utilisation de produits chimiques de recherche strictement pour les tests in vitro et l'expérimentation de laboratoire uniquement. Toutes les informations sur les produits disponibles sur ce site Web sont à des fins éducatives uniquement. L'introduction corporelle de toute nature dans l'homme ou les animaux est strictement interdite par la loi. Ce produit ne doit être géré que par des professionnels agréés et qualifiés. Ce produit n'est pas une drogue, de la nourriture ou un cosmétique et peut ne pas être mal étendu, mal utilisé ou erroné comme drogue, aliment ou cosmétique.
Fragment 176-191 (version modifiée OFAOD9604) est un petit morceau d'hormone de croissance humaine (HGH) qui est parfois appelé «fragment lipolytique». Le fragment 176-191 a gagné ce dernier nom en raison du fait que la recherche en laboratoire l'a montré pour améliorer la combustion des graisses, en particulier chez la souris génétiquement conçue pour produire de grands réserves de graisses. Le fragment 176-191 a été fortement recherché sur des modèles animaux car même si elle préserve les effets de brûlure des graisses de HGH, il évite certains autres effets de sa protéine parent tels que l'augmentation des niveaux de facteur de croissance de type insuline (IGF-1), un impact négatif sur le métabolisme des glucides, la modification de la sensibilité à l'insuline, l'augmentation de la croissance osseuse longue et du tout. Les effets ciblés du fragment 176-191 le rendent utile pour explorer le métabolisme des graisses humaines et peuvent éventuellement fournir la base du développement de médicaments anti-obésité.
Source:Se publier
Séquence:Tyr-leu-arg-ile-val-gln-cys-arg-ser-val-glu-gly-ser-cys-gly-phe
Formule moléculaire:C78H125N23O23S2
Poids moléculaire:1817.12 g / mol
Numéro CAS:66004-57-7
La recherche chez les animaux a révélé que l'extrémité C-terminale de HGH est principalement responsable des effets hypoglycémiques (abaissement de la glycémie) de la protéine. Les tests d'au moins six fragments différents dérivés de cette section de HGH ont montré que le fragment 176-191 est le dérivé synthétique le plus efficace de HGH pour abaisser la glycémie. Cet effet est secondaire à une augmentation soutenue des taux d'insuline plasmatique[1]. There is some interest in using fragment 176-191 as a treatment for both prediabetes and type 2 diabetes.
Fragment 176-191 has earned the nickname of “lipolytic fragment” because testing in mice has revealed the peptide to have substantial fat burning and weight loss properties. It is thought that this action is mediated through an increase in production of beta-3 adrenergic receptors (β3-AR or ADRB3)[2]. Agonist action at ADRB3 is known to directly increase fat burning in adipose tissue and is also responsible for thermogenesis in skeletal muscle[3]. Mice that have been genetically modified to produce no ADRB3 do not respond to the lipolytic effects of hGH or fragment 176-191[2].
Studies show that the increased fat burning associated with fragment 176-191 directly correlates with energy expenditure and thus weight reduction, leading to a nearly 50% reduction in weight gain in obese animals over a three-week course[4]. Interestingly, the weight loss effects were seen only in obese mice, with lean mice maintaining normal body weight, on average, even when exposed to fragment 176-191[2]. These findings indicate that there are secondary regulatory pathways for lipolysis that override ADRB3 function when body weight is at or near ideal, opening up areas for additional research into energy homeostasis.
Body weight in genetically obese mice after two weeks of treatment with a single daily dose of fragment 176-191
Source: Oxford Academic
Effect of saline (control), fragment 176-191, and hGH on white adipose tissue mass in obese mice over 14 days
Source: Oxford Academic
Though fragment 176-191 is primarily of interest for its lipolytic properties, the peptide is under investigation for other possible benefits. Of note, a 2015 article out of Korea revealed that fragment 176-191 may be able to potentiate the effects of hyaluronic acid injections in promoting cartilage regeneration. Studies in rabbits indicated that weekly injections of fragment 176-191 increase laboratory measures of cartilage growth and that co-administration of the peptide with hyaluronic acid (HA) produces even more substantial effects. Similarly, the study found that fragment 176-191, both alone and in combination with HA, reduces disability associated with osteoarthritis. There is hope that this may lead to advanced therapies for osteoarthritis and may even eliminate the need for surgery in certain settings[7].
There is some concern that the use of hGH or its derivatives for weight control may have unwanted side effects. This concern arises from the fact that studies of hGH have shown that long-term exogenous administration, while increasing lean body mass and decreasing adipose tissue, can also cause:
In 2013, a study published in the Journal of Endocrinology and Metabolism evaluated six studies of fragment 176-191 to assess the rate and significance of negative effects associated with the peptide. The study, included only research that followed the randomized, double-blinded, placebo-controlled model of a phase IIb clinical trial in order to keep the highest possible standards of evidence. It found that IV and oral administration of Fragment 176-191, when compared to placebo, led to no changes in:
The results of this meta-analysis suggest that fragment 176-191 offers many of the benefits of hGH without the associated negative (and often serious) side effects. These findings further the argument for pursuing regulatory approval for use of fragment 176-191 in the clinical setting, but also offer insight into the regulation of human growth, fat deposition, and energy homeostasis. These findings make it clear that it is possible to target fat loss without affecting energy homeostasis in other nutrient pathways, opening the door for a deeper exploration of human energy regulation and methods of manipulating it.
It is worth noting that while hGH has anabolic effects on muscle, fragment 176-191 was specifically selected for its ability to avoid anabolism entirely. This is critical to ensuring that the peptide has targeted lipolytic effects and does not produce acromegaly or any of the other conditions associated with hGH administration. Studies in mice reveal that fragment 176-191 does not increase cell proliferation[6].
The primary area of research for fragment 176-191 is in weight loss and lipolysis where significant effort is being expended to learn how the peptide can be used to understand fat metabolism and energy homeostasis. The most active secondary area of research is in connective tissue regeneration, particularly cartilage repair.
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Frank NG, M.D. is one of the leading scientists discovering how both AOD9604 and Fragment 176-191 function. He extensively studied their effects on lipid metabolism in obese mice, fat oxidation, weight loss, oral digestion, glucose transport, and hyperglycemia. He has over 64 publications and studies at the Department of Biochemistry and Molecular Biology — Monash University, Australia.
Frank NG, M.D. is being referenced as one of the leading scientists involved in the research and development of Fragment 176-191. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
PeptideGurus is a leading supplier of American-made research peptides, offering top-quality products at competitive prices. With a focus on excellence and customer service, they ensure a secure and convenient ordering process with global shipping.
© Copyright Peptide Gurus 2024. All rights reserved.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration or HEALTH CANADA. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
PeptideGurus is a chemical supplier. PeptideGurus is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Peptide Sciences is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
CONTACT
